Détail de l'auteur
Documents disponibles écrits par cet auteur
trié(s) par (Pertinence décroissant(e), Date de parution décroissant(e), Date de parution décroissant(e), Système de projection du document croissant(e)) Mettre toutes les notices dans le panier Faire une suggestion Ajouter un critère de recherche
From diagnosis to prognosis: Revisiting the meaning of muscle ISG15 overexpression in juvenile inflammatory myopathies
Hou C, Durrleman C, Periou B, et al.
Arthritis & rheumatology (Hoboken, N.J.), 2020
Circulating interferon-alpha measured with a highly sensitive assay as a biomarker for juvenile inflammatory myositis activity
Melki I, Devilliers H, Gitiaux C, et al.
Arthritis & rheumatology (Hoboken, N.J.), 2020, 72, 1, p 195
Severe Abdominal Manifestations in Juvenile Dermatomyositis
Besnard C, Gitiaux C, Girard M, et al.
Journal of pediatric gastroenterology and nutrition, 2019
Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-alpha signalling
Melki I, Devilliers H, Gitiaux C, et al.
Rheumatology (Oxford, England), 2019
Inhibition of IFNalpha secretion in cells from patients with juvenile dermatomyositis under TBK1 inhibitor treatment revealed by single-molecular assay technology
Gitiaux C, Bondet V, Bekaddour N, et al.
Rheumatology (Oxford, England), 2019
Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis
Aouizerate J, De Antonio M, Bader-Meunier B, et al.
Rheumatology (Oxford, England), 2018, 57, 5, p 873
Presentations and outcomes of juvenile dermatomyositis patients admitted to intensive care units
Besançon A, Brochard K, Dupic L, et al.
Rheumatology (Oxford, England), 2017, 56, 10, p 1814
Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial
Ruperto N, Pistorio A, Oliveira S, et al.
Lancet (London, England), 2016, 387, 10019, p 671
Vasculopathy-related clinical and pathological features are associated with severe juvenile dermatomyositis
Gitiaux C, De Antonio M, Aouizerate J, et al.
Rheumatology (Oxford), 2016, 55, 3, p 470
Mycophenolate mofetil in juvenile dermatomyositis : a case series
Dagher R, Desjonquères M, Duquesne A, et al.
Rheumatology international, 2012, 32, 3, p. 711-716
Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the french autoimmunity and rituximab registry
Bader-Meunier B, Decaluwe H, Barnerias C, et al.
Journal of rheumatology, 2011, 38, 7, p. 1436-1440
The pediatric rheumatology international trials organization provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis
Ruperto N, Pistorio A, Ravelli A, et al.
Arthritis care and research, 2010, 62, 11, p. 1533-1541
Juvenile dermatomyositis
Quartier P, Gherardi RK
Handbook of Clinical Neurology (Pediatric Neurology), pharma, 113, 3rd series, cha, p. 1457-1463, p. 149
